<DOC>
	<DOCNO>NCT00158717</DOCNO>
	<brief_summary>To investigate durability HBeAg seroconversion patient chronic hepatitis B virus infection ( HBV ) seroconverted participate previous Gilead-sponsored study adefovir dipivoxil .</brief_summary>
	<brief_title>Observational Study Durability Seroconversion Chronic HBV Patients Who Seroconverted Previous Gilead-Sponsored Study ADV .</brief_title>
	<detailed_description>The primary objective study investigate durability HBeAg seroconversion patient chronic hepatitis B virus infection ( HBV ) seroconverted participate previous Gilead-sponsored study adefovir dipivoxil . The secondary objective study investigate durability HBeAg loss patient chronic hepatitis B virus infection ( HBV ) experience durable HBeAg loss participate previous Gilead-sponsored study adefovir dipivoxil .</detailed_description>
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis B</mesh_term>
	<criteria>Must meet inclusion criterion none exclusion criterion must demonstrate HBeAg seroconversion durable HBeAg loss define protocol one follow Gileadsponsored study : GS96412 , GS98437 , GS00461 ongoing future Gileadsponsored study identify Sponsor eligible study . Other patient enrol close Gileadsponsored study ADV ( GS94404 , GS96412 Initial Phase GS96413 ) previously demonstrate seroconversion durable HBeAg loss participation evaluate clinical research organization ( CRO ) medical monitor participation study case case basis . Have document negative serum HBeAg without positive antiHBe present two study visit prior final visit previous study . A patient document negative serum HBeAg without positive antiHBe must also undetectable serum HBV DNA ( less 1000 copies/mL use Roche Amplicor PCR Assay ) normalize ALT ( less ULN ) confirm two study . All patient must able give write informed consent comply requirement study . Patients seroconvert experience durable HBeAg loss participation study GS00480 eligible . Any serious active medical psychiatric illness , opinion investigator would interfere patient treatment , assessment compliance protocol . Receiving exclude medication list protocol . Inability comply study requirement .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2014</verification_date>
	<keyword>Chronic Hepatitis B</keyword>
</DOC>